Metagenomi Therapeutics, Inc. revenue

Metagenomi Therapeutics, Inc.'s revenue was $25.2m in fiscal 2025, down 51.8% on the year before. Over the last twelve months it was $22.3m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Metagenomi Therapeutics, Inc.: revenue history, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMMar 2026
Revenue	45	52	25	22
Growth on the year before	—	+16.8%	−51.8%	—

US$ millions unless shown otherwise. Fiscal quarters.

Metagenomi Therapeutics, Inc.: revenue history, quarterly
Quarter	2024 Q2Jun 2024	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026
Revenue	20	12	10	4	9	9	4	1
Growth on the same quarter a year before	—	—	—	—	−57.5%	−24.8%	−59.3%	−69.8%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Metagenomi Therapeutics, Inc.	$22.3m	-50.7%	—
Janux Therapeutics, Inc.	$24.0m	5367.0%	45.7%
Crispr Therapeutics AG	$25.2m	-34.3%	-47.1%
Abeona Therapeutics Inc.	$25.5m	-87.7%	212.0%
Scynexis Inc	$19.2m	489.8%	-47.9%
Celularity Inc	$18.7m	-58.1%	7.2%

Compare with peers

Head to head: JANX vs MGX CRSP vs MGX ABEO vs MGX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Metagenomi Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Metagenomi Therapeutics, Inc.